Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
398 stopped studies mapped to Sarcoma and descendants · 90% state a reason
Over the 398 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02425878 | Ulipristal Acetate 10 mg and Asisted Reproduction | Phase 3 | terminated | Apr 24, 2015 | Instituto Valenciano de Infertilidad, IVI VALENCIA | Lack of availibility of eligible subjects | Other (stated, no rule matched) |
| NCT02547376 | Genetic and Telomere Characteristics of High of Grade Soft Tissue Sarcomas | — | terminated | Sep 11, 2015 | University Hospitals, Leicester | Covid-19 | COVID-19 / pandemic |
| NCT03013127 | A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not…(PROMO) | Phase 2 | terminated | Jan 6, 2017 | Oslo University Hospital | Inclusion of patients was stopped because ≤2 patients had clinical benefit. | Other (stated, no rule matched) |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT04098887 | Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or… | N/A | withdrawn | Sep 23, 2019 | Washington University School of Medicine | Investigator decided to not go forward with the study. | Investigator |
| NCT02929394 | Trabectedin Maintenance Post 1st-line in STS | Phase 3 | terminated | Oct 11, 2016 | European Organisation for Research and Treatment of Cancer - EORTC | Poor accrual | Enrollment / accrual |
| NCT01280045 | Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal… | N/A | terminated | Jan 20, 2011 | University of Sao Paulo | No grant was received then we stopped the recruitment | Enrollment / accrual |
| NCT01738724 | Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared… | Phase 4 | terminated | Nov 30, 2012 | University of Sao Paulo | PI went for a post-doc course and when he came back he moved for another job | Other (stated, no rule matched) |
| NCT00880542 | Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone… | Phase 2 | terminated | Apr 13, 2009 | Jonsson Comprehensive Cancer Center | The study lost funding. | Funding |
| NCT03509207 | Vorinostat (SAHA) in Uterine Sarcoma | Phase 2 | terminated | Apr 26, 2018 | Medical University of Graz | The early termination was NOT due to safety reasons, terminated because of the very slow… | Safety / toxicity |
| NCT03698227 | OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients | Phase 2 | terminated | Oct 5, 2018 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Lack of efficacy on olaratumab | Efficacy / futility |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab… | Phase 2 | terminated | Nov 20, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or… | Phase 1 | terminated | Mar 12, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT03613259 | Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft… | Early Phase 1 | withdrawn | Aug 3, 2018 | OHSU Knight Cancer Institute | Funding expired | Funding |
| NCT03104335 | Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial | Phase 2 | withdrawn | Apr 7, 2017 | Peking University People's Hospital | Not enough patients | Other (stated, no rule matched) |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or… | Phase 3 | terminated | Feb 15, 2012 | Gynecologic Oncology Group | not stated | Not stated |
| NCT03520959 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With… | Phase 3 | terminated | May 11, 2018 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Study was terminated due to sponsor's decision. | Sponsor / business decision |
| NCT04132349 | Ulipristal Acetate in Symptomatic Uterine Fibroid | Phase 4 | terminated | Oct 18, 2019 | Mỹ Đức Hospital | Ulipristal Acetate was recalled | Other (stated, no rule matched) |
| NCT02797405 | Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay(THEODORA) | N/A | terminated | Jun 13, 2016 | Centre Leon Berard | Withdrawal of analysis study Partner. | Other (stated, no rule matched) |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and… | Phase 1 | terminated | Jun 14, 2010 | National Cancer Institute (NCI) | Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same… | Enrollment / accrual |
| NCT01313429 | Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell… | Phase 1 | terminated | Mar 11, 2011 | National Cancer Institute (NCI) | Per stopping rule if 12 patients underwent immune response analysis after 6 vaccinations and none… | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT00038142 | Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's… | Phase 2 | terminated | May 30, 2002 | M.D. Anderson Cancer Center | Low Accrual | Enrollment / accrual |
| NCT00752206 | A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent… | Phase 2 | terminated | Sep 15, 2008 | Sarcoma Alliance for Research through Collaboration | The Data Safety Monitoring Board (DSMB) recommended study termination for slow accrual and futility. | Safety / toxicity |
| NCT03699176 | Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 7) | Phase 3 | withdrawn | Oct 9, 2018 | Bayer | No patient was recruited, study withdrawn for feasibility reasons. | Enrollment / accrual |
| NCT00005655 | Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer | Phase 1 | terminated | May 5, 2000 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | Phase 1 | terminated | Jan 29, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00287495 | BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma | Phase 1 | terminated | Feb 6, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00717522 | Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma | Phase 2 | terminated | Jul 17, 2008 | Celgene | Study enrollment was terminated due to a corporate strategic decision unrelated to patient safety. | Safety / toxicity |
| NCT00859456 | Sunitinib in Certain Subtypes of Soft Tissue Sarcomas | Phase 2 | terminated | Mar 11, 2009 | Columbia University | Closed by pharmaceutical sponsor | Other (stated, no rule matched) |
| NCT01886105 | Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma | Phase 2 | terminated | Jun 25, 2013 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low accrual and loss of funding | Enrollment / accrual |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Phase 1 | terminated | Jun 10, 2016 | Virginia Commonwealth University | Study drug no longer being clinically developed by manufacturer | Drug supply |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT02441309 | A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)(MEMOS) | Phase 2 | terminated | May 12, 2015 | University of Oxford | Failed to recruit sufficient numbers of patients in the funded period | Enrollment / accrual |
| NCT03397186 | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | Phase 2 | withdrawn | Jan 11, 2018 | Fred Hutchinson Cancer Center | Administrative | Other (stated, no rule matched) |
| NCT02683148 | DHEA in Synovial Sarcoma Patients | Phase 1 | terminated | Feb 17, 2016 | Washington University School of Medicine | The trial did not show any positive effects. | Other (stated, no rule matched) |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory… | Phase 2 | withdrawn | Feb 23, 2016 | Washington University School of Medicine | Could not recruit any participants | Enrollment / accrual |
| NCT01834703 | Uterine Artery Embolization(UAE) Versus High-Intensity-Focused-Ultrasound(HIFU) for… | N/A | terminated | Apr 18, 2013 | Chinese University of Hong Kong | not stated | Not stated |
| NCT03210324 | A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With… | Phase 4 | terminated | Jul 6, 2017 | China Resources Zizhu Pharmaceutical Co., Ltd. | It is difficult to recruit enough participants | Enrollment / accrual |
| NCT01957709 | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma | Early Phase 1 | terminated | Oct 8, 2013 | Fred Hutchinson Cancer Center | Enough samples were collected for data analysis. | Other (stated, no rule matched) |
| NCT02005614 | A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI… | N/A | terminated | Dec 9, 2013 | Yale University | Unable to recruit patients. | Enrollment / accrual |
| NCT02575066 | Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma…(PASART-2) | Phase 2 | terminated | Oct 14, 2015 | The Netherlands Cancer Institute | stopping rule | Other (stated, no rule matched) |
| NCT02811159 | An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the… | Phase 2 | terminated | Jun 23, 2016 | Repros Therapeutics Inc. | Business decision | Sponsor / business decision |
| NCT02718482 | Phase II Trial for the Treatment of Relapsed Osteosarcoma(OsteoREC2015) | Phase 2 | terminated | Mar 24, 2016 | Italian Sarcoma Group | Not adequate enrollment (sample size not possible to reach) | Enrollment / accrual |
| NCT03773510 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin(TRADITIONS) | Phase 3 | withdrawn | Dec 12, 2018 | Italian Sarcoma Group | Not approved by the coordinating Ethical Committee | Other (stated, no rule matched) |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing…(N1) | — | terminated | Sep 14, 2016 | CureOne | Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. | Other (stated, no rule matched) |
| NCT00265902 | Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma | N/A | terminated | Dec 15, 2005 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | low accrual | Enrollment / accrual |
| NCT02557854 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric… | Phase 1 | withdrawn | Sep 23, 2015 | Theodore Laetsch | Lack of enrollment | Enrollment / accrual |
| NCT03437070 | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent… | Phase 1 | withdrawn | Feb 19, 2018 | University of Miami | Sponsor Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 14, 2020source: clinicaltrials